Affiliation:
1. LLC "JVS Diagnostics"
2. Shemaykin‑Ovchinnikov Institute of Bioorganic Chemistry RAS
3. Institute of Personalized Oncology, Center for Digital Bio design and Personalized Healthcare, First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Abstract
Purpose of the study. Evaluation of the diagnostic characteristics of the CA‑62 marker for epithelial carcinomas for detecting early‑stage prostate cancer in a double‑blind clinical study. This study is also focused on the possibility of using the CA‑62 antigen as an auxiliary tool for decision‑making in prostate cancer diagnosis.Patients and methods. A blinded clinical study was conducted on 325 clinically verified blood serum samples. This includes 144 prostate cancer samples, 79 generally healthy volunteers‑men and 102 samples from patients with benign prostatic hyperplasia (BPH). Quantitative determination of the total and free prostate specific antigen (PSA) levels, as well as the CA‑62 marker of serum samples was performed using the electrochemiluminescent immunoassay ECLIA Elecsys Total and Free PSA (COBAS, Roche Diagnostics GmbH, Germany, EU) and the chemiluminescent immunoassay CLIA‑CA‑62 (JVS Diagnostics LLC, Moscow, RF).Results. A comparison of the CA‑62 level with the results for total and free PSA, as well as other diagnostic methods (PCA3, PHI) for the analysis of the BPH and prostate cancer groups was performed. The results show that the CA‑62 marker has the highest PPV (94.4 %) and NPV (93.1 %). This may increase the reliability of the decision related to the presence of PC and be used by doctors as an argument as an argument for a prostate biopsy referral. It has been demonstrated that using the novel cancer marker CA‑62 makes it possible to detect up to 90 % of the early‑stage prostate cancer with 97.2 % specificity (AUC = 0.969).Conclusion. Using the CA‑62 marker as an auxiliary diagnostic method within the PSA “grey zone” (from 2.5 to 10 ng/ml) made it possible to significantly increase the accuracy of detecting the PC early stages at biopsy up to 93.1 %. It will help the doctors to effectively differentiate between prostate cancer and benign prostatic hyperplasia.
Subject
Microbiology (medical),Immunology,Immunology and Allergy
Reference30 articles.
1. International Agency for Research on Cancer. GLOBOCAN 2020: Cancer incidence and mortality worldwide in 2020. Available at: https://gco.iarc.fr/today/fact-sheets-cancers. Accessed: 10.02.2023.
2. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Edited by Kaprin AD, Starinsky VV, Shakhzadova AO. Мoscow: P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation, 2021, 252 p. (In Russ.). Available at: https://glavonco.ru/cancer_register/Забол_2020_Электр.pdf. Accessed: 10.02.2023.
3. Каприн А. Д. Алексеев Б. Я., Матвеев В. Б., Пушкарь Д. Ю., Говоров А. В., Горбань Н. А., и др. Рак предстательной железы. Клинические рекомендации. Современная онкология. 2021;23(2):211–247. https://doi.org/10.26442/18151434.2021.2.200959
4. Guide to cancer early diagnosis. World Health Organization, 2018, ISBN 978‑92‑4‑451194‑7. Available at: https://apps.who.int/iris/bitstream/handle/10665/272264/9789244511947-rus.pdf. Accessed 10.02.2023.
5. Lundgren PO, Kjellman A, Norming U, Gustafsson O. Long‑Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. J Urol. 2018 Jul;200(1):82–88. https://doi.org/10.1016/j.juro.2018.01.080
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献